Breaking News
Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments
Obsidian Therapeutics, a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer (CEO). A highly experienced clinician and researcher with an extensive industry background in the development of tumor-infiltrating lymphocyte (TIL) treatments for cancer, Dr. Jagasia joins Obsidian as it focuses on the advancement and expansion of its clinical program.
Prior to joining Obsidian as CEO, Dr. Jagasia was Executive Vice President, Medical Affairs at Iovance Biotherapeutics, Inc. (“Iovance”), where he was responsible for managing national medical affairs, strategic congress planning, advocacy, strategic alliances and external research collaborations. Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC. Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center. Dr. Jagasia has his M.B.B.S from the GS Medical College & KEM Hospital, an M.S. and a Master of Management in Health Care from Vanderbilt University.
Obsidian has also named Parameswaran Hari, M.D., M.S., as Chief Development Officer. Dr. Hari joins Obsidian from Iovance, where he was Senior Vice President, Clinical Science. He brings decades of experience designing, managing and leading complex cell and gene therapy clinical programs, including TIL therapies. Dr. Hari was formerly the Chief of Hematology and Oncology at the Medical College of Wisconsin and served the American Society of Transplantation and Cellular Therapy (ASTCT) as its secretary.
Additionally, Obsidian announces the appointment of Matthew Norkunas, M.D., M.B.A., to its Board of Directors. Dr. Norkunas is an experienced biotechnology executive, currently serving as Chief Financial Officer at Generation Bio. He has previously served as Chief Financial officer at SomaLogic and has a background in healthcare investing and medicine. Dr. Norkunas began his career as a practicing anesthesiologist. Dr. Norkunas earned a Master of Business Administration from Columbia Business School, a medical degree from University of Maryland School of Medicine, and a Bachelor of Arts degree from St. Mary’s College of Maryland.
“I am delighted to welcome Drs. Jagasia and Hari to the Obsidian leadership team. Their appointments deepen Obsidian’s clinical expertise and align with the Company’s current focus on clinical development and advancing its lead TIL program, OBX-115,” said Maria Fardis, Ph.D., Executive Chair of Obsidian’s Board of Directors. “I am appreciative of the critical progress made by the prior leadership in advancing Obsidian through preclinical development and successfully into the clinic. I am also pleased to announce Dr. Norkunas’ appointment to the Board. He brings deep operational experience and strong financial expertise and I look forward to his future contributions to the Board. The Company is well poised for continued advancement in line with our plan.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more